Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Change in Inventory (2023 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Change in Inventory for 3 consecutive years, with -$2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Inventory fell 135.9% to -$2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.8 million, a 91.81% increase, with the full-year FY2025 number at $11.8 million, up 91.81% from a year prior.
  • Change in Inventory was -$2.0 million for Q4 2025 at Phathom Pharmaceuticals, down from -$395000.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $12.3 million in Q1 2025 to a low of -$2.0 million in Q4 2025.
  • A 3-year average of $2.7 million and a median of $417000.0 in 2024 define the central range for Change in Inventory.
  • Biggest YoY gain for Change in Inventory was 2863.46% in 2025; the steepest drop was 194.5% in 2025.
  • Phathom Pharmaceuticals' Change in Inventory stood at $9.3 million in 2023, then crashed by 40.24% to $5.6 million in 2024, then plummeted by 135.9% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Change in Inventory are -$2.0 million (Q4 2025), -$395000.0 (Q3 2025), and $1.8 million (Q2 2025).